Danaher Co. (NYSE:DHR) Shares Sold by Franklin Street Advisors Inc. NC

Franklin Street Advisors Inc. NC lessened its stake in Danaher Co. (NYSE:DHR) by 0.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 65,412 shares of the conglomerate’s stock after selling 620 shares during the period. Franklin Street Advisors Inc. NC’s holdings in Danaher were worth $15,132,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. Mirova increased its holdings in Danaher by 1.1% during the 2nd quarter. Mirova now owns 4,159 shares of the conglomerate’s stock worth $998,000 after purchasing an additional 46 shares during the period. Apella Capital LLC increased its stake in shares of Danaher by 2.0% during the third quarter. Apella Capital LLC now owns 2,332 shares of the conglomerate’s stock worth $579,000 after buying an additional 46 shares during the period. Nations Financial Group Inc. IA ADV raised its holdings in Danaher by 0.8% in the first quarter. Nations Financial Group Inc. IA ADV now owns 6,064 shares of the conglomerate’s stock valued at $1,779,000 after acquiring an additional 46 shares in the last quarter. Peddock Capital Advisors LLC lifted its stake in Danaher by 0.9% in the third quarter. Peddock Capital Advisors LLC now owns 5,523 shares of the conglomerate’s stock worth $1,370,000 after acquiring an additional 47 shares during the last quarter. Finally, IMS Capital Management grew its holdings in Danaher by 0.4% during the 2nd quarter. IMS Capital Management now owns 11,046 shares of the conglomerate’s stock worth $2,651,000 after acquiring an additional 49 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In related news, Director Walter G. Lohr sold 3,289 shares of Danaher stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $251.15, for a total transaction of $826,032.35. Following the sale, the director now directly owns 14,129 shares of the company’s stock, valued at $3,548,498.35. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Walter G. Lohr sold 3,289 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $251.15, for a total transaction of $826,032.35. Following the sale, the director now directly owns 14,129 shares of the company’s stock, valued at approximately $3,548,498.35. The disclosure for this sale can be found here. Insiders have sold 32,957 shares of company stock worth $8,265,802 in the last ninety days. Insiders own 11.10% of the company’s stock.

Danaher Trading Up 0.4 %

Danaher stock opened at $249.72 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. The company has a market capitalization of $184.72 billion, a price-to-earnings ratio of 39.08, a PEG ratio of 3.78 and a beta of 0.84. The company’s fifty day moving average price is $247.17 and its two-hundred day moving average price is $230.53. Danaher Co. has a one year low of $182.09 and a one year high of $259.00.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.18. The business had revenue of $6.41 billion during the quarter, compared to the consensus estimate of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. Danaher’s quarterly revenue was down 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.87 EPS. On average, analysts forecast that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be issued a $0.27 dividend. The ex-dividend date is Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. Danaher’s dividend payout ratio is 16.90%.

Analyst Ratings Changes

DHR has been the topic of several research analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 20th. Royal Bank of Canada upped their target price on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. HSBC began coverage on shares of Danaher in a research note on Monday, December 18th. They set a “hold” rating on the stock. Wolfe Research started coverage on Danaher in a research report on Wednesday, December 13th. They issued a “peer perform” rating for the company. Finally, Barclays cut shares of Danaher from an “overweight” rating to an “equal weight” rating and set a $240.00 price objective for the company. in a research note on Wednesday, January 24th. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $266.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.